Physician profile
Mark A Galles
NPI 1982681482
$17,478.44
in general payments reported to CMS, 2019-2025
65 companies · $2,560 in 2025
The $2,560 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,758 · 2020: $1,228 · 2021: $2,283 · 2022: $2,844 · 2023: $3,053 · 2024: $2,753 · 2025: $2,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,305 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,304.94 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,207.34 | 2019-2025 | |
| Novo Nordisk INC | $1,386.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,134.37 | 2019-2025 | |
| Amgen INC. | $949.76 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $897.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $891.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $824.02 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $816.80 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $710.98 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $660.91 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $653.76 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $542.95 | 2019-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $511.88 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Novartis Pharmaceuticals Corporation | $484.71 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $420.00 | 2021-2025 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Galles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.